PEYROFLEX, 410 mg capsules, 60 pcs.

PEYROFLEX works on various mechanisms of scar tissue formation to alleviate Peyronie's disease and slow down the development of plaque.

Characteristics of the components of the PEYROFLEX" complex ("PEYROFLEX")

Numerous literary medical data * have confirmed the efficacy and safety of the components of the PEYROFLEX complex when used in people with Peyronie's disease:

Para-aminobenzoic acid (PABA)

PABA is an organic compound, an amino acid derivative of benzoic acid, widely distributed in nature. PABA is a precursor in the biosynthesis of important cofactors - tetrahydrofolate and tetrahydromethanopterin. As an integral part of tetrahydrofolate, the para-aminobenzoic acid residue is involved in the synthesis of nucleic acids (RNA and DNA). It has both anti-inflammatory and anti-fibrotic effects and is used to treat fibrosing conditions such as Dupuytrien's contracture. Potassium para-aminobenzoate stabilizes a specific tissue enzyme and has a direct inhibitory effect on the cell skeleton of fibroblasts that form a fibrous plaque [13]. Salts of para-aminobenzoic acid have been used for many years to treat Peyronie's disease [14].Numerous clinical studies of derivatives of para-aminobenzoic acid have shown its high efficiency in the formation of curvature of the penis.

D -? - tocopherol

D -? - Tocopherol is a fat-soluble vitamin E with antioxidant properties that limits oxidative stress.

In Peyronie's disease in the acute and chronic phases of plaque formation, an excessive release of reactive oxygen species occurs, this point of application makes D -? - tocopherol an ideal option for drug therapy [1].

D - β-tocopherol inhibits the production of transforming growth factor-β 1 (TGF-β 1).

He is responsible for the development of connective tissue.

It was shown that D -? - tocopherol slows down the division of fibroblasts (cells responsible for the formation of fibrous plaques) in pathological human fibrosis [2,3].

D -? - tocopherol interacts with the nuclear factor NF -? AppaB, also preventing the release of proinflammatory molecules (cytokines)

D - β - tocopherol inhibits the activity of cyclooxygenase 2 [4–6].

L-carnitine tartrate

This molecule is very similar to an amino acid in humans, it is synthesized in the liver, brain and kidneys from the essential amino acids lysine and methionine by means of ALC transferase. The carnitine system consists of L-carnitine, its esters (acetyl-L-carnitine, propionyl-L-carnitine) and a complex enzymatic system located in the mitochondrial membrane. L-carnitine tartrate prevents the proliferation of fibroblasts and the formation of collagen by reducing the activity of free radicals and the nutrient cell calcium concentration. It also protects and repairs cells with damage caused by inflammation and microvascular trauma [19]. L-Carnitine Tartrate helps the body repair damaged cells. Carnitines stabilize the fluidity of cell membranes, which has a positive effect on cell integrity [20,21].Various forms of L-carnitine have been used successfully to treat Peyronie's disease. In randomized controlled trials, the use of L-carnitine for 3 months relieved pain during erection in 92% of men, while there was a decrease in the mean curvature of the penis by 7.5 ° and a decrease in plaque size by 48.8 mm2 [20] [21] ...

* Sources of literary medical data:

1. Sikka SC et al. Int. J. Impot. Res. 2002. Vol. 14, No. 5. P. 353–360. 2. Tasanarong A. et al. J. Med. Assoc. Thai. 2011. Vol. 94 Suppl 7.P. S1-9. 3. Haas AL et al. Ophthalmic Res. 1996. Vol. 28, No. 3. P. 171–175. 4. Godbout JP et al. J. Neuroimmunol. 2005. Vol. 169, no. 1–2. P. 97-105. 5. Jiang Q. et al. Proc. Natl. Acad. Sci. 2008. Vol. 105, No. 51. P. 20464–20469. 6. Fazzio A., Marilley D., Azzi A. Biochem. Mol. Biol. Int. 1997. Vol. 41, No. 1. P. 93-101. 7. Scardino PL, Scott WW Ann. NY Acad. Sci. 1949. Vol. 52, No. 3. P. 390–396. 8. Chesney J. Br J Urol. 1975. Vol. 47. P. 209-218. 9. Pryor J., Farrell C. Prog Reprod Biol Med. 1983. Vol. 9. P. 41–45. 10. Devine CJ, Horton C. Semin Urol. 1987. Vol. 5. P. 251-261. 11. Halal AA, Geavlete P., Ceban E. J Med Life. 2012. 12. Paulis G. et al. Andrology. 2013. Vol. 1, No. 1. P. 120–128. 13.Nehra A. et al. J. Urol. 2015. Vol. 194, No. 3. P. 745-753. 14. Hauck EW et al. Urologe. 2005. Vol. 44, No. 10. P. 1189-1196. 15. ZARAFONETIS CJ, HORRAX TMJ Urol. 1959. Vol. 81, No. 6. P. 770-772. 16. Hasche-Klunder R. Urologe. A. 1978. Vol. 17, No. 4. P. 224–227. 17. Riley A. BR J Sex Med. 1979. Vol. 6. P. 29–33. 18. Carson CC Tech. Urol. 1997. Vol. 3, no. 3. P. 35–139. 19. Jack GS, Gonzalez-Cadavid N., Rajfer J. Curr. Urol. Rep. 2005. Vol. 6, No. 6. P. 454–460. 20. Biagiotti G., Cavallini G. BJU Int. 2001. Vol. 88, No. 1. P. 63–67. 21. Cavallini G. et al. BJU Int. 2002. Vol. 89, No. 9. P. 895-900.224-227. 17. Riley A. BR J Sex Med. 1979. Vol. 6.P. 29–33. 18. Carson CC Tech. Urol. 1997. Vol. 3, no. 3. P. 35–139. 19. Jack GS, Gonzalez-Cadavid N., Rajfer J. Curr. Urol. Rep. 2005. Vol. 6, No. 6. P. 454–460. 20. Biagiotti G., Cavallini G. BJU Int. 2001. Vol. 88, No. 1. P. 63–67. 21. Cavallini G. et al. BJU Int. 2002. Vol. 89, No. 9. P. 895-900.224-227. 17. Riley A. BR J Sex Med. 1979. Vol. 6. P. 29–33. 18. Carson CC Tech. Urol. 1997. Vol. 3, No. 3. P. 35–139. 19. Jack GS, Gonzalez-Cadavid N., Rajfer J. Curr. Urol. Rep. 2005. Vol. 6, No. 6. P. 454–460. 20. Biagiotti G., Cavallini G. BJU Int. 2001. Vol. 88, No. 1. P. 63–67. 21. Cavallini G. et al. BJU Int. 2002. Vol. 89, No. 9. P. 895-900.

INN / Active ingredient

L-carnitine tartrate, para-aminobenzoic acid, D -? - tocopherol.

Structure

L-carnitine tartrate, para-aminobenzoic acid, D -? - tocopherol.

Specifications

Category

Regenerating agents

Package quantity, pcs

60

Scope of the drug

Genitourinary system

Minimum age from

18 years

For children

No

Release form

Capsules

Scope of application

Urology

Scope of use

Intimate area

Vacation conditions

Without recipe

Contraindications dietary supplements

Dietary supplement.

NOT A DRUG

Manufacturer country

Russia

Expiration date in days

730

Drug action

Anti-scar

Brand name

SSH PHARMA

A type

Dietary supplement

Package weight, g

55

Mode of application

:

Adults take 1 capsule 2 times a day with meals.

Duration of admission:

1 month.

If necessary, the reception can be repeated.

Information on technical characteristics, delivery set, country of manufacture "